Clinical trials
Advanced Lung Cancer clinical trials
Below are recruiting advanced lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07361237RecruitingPhase 1
HJ-004-02 tablet for EGFR-mutated lung cancer
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT06873555RecruitingPhase 1/Phase 2
Study of a new drug for ovarian cancer and other advanced solid tumors
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
Bengbu, AnhuiAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06121505RecruitingPhase 2
Low-dose radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding low-dose radiation and a type of targeted radiation (SBRT) to a combination of immunotherapy (sintilimab) and chemotherapy works better than immunotherapy and chemotherapy alone for people with advanced squamous cell lung cancer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Daphne, AlabamaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT04151940Recruiting
PET/CT scan changes during chemo with immune therapy
This study looks at how PET/CT scan results change while you receive chemo plus an immune therapy (a PD-1/PD-L1 medicine) for stage IV lung cancer. The goal is to better understand what the scans mean during treatment, which may help guide care in the future.
Seattle, WashingtonAges 18 years+ - NCT07770100RecruitingPhase 2
Matching immunotherapy and targeted radiation for advanced cancer
This trial tests combining immunotherapy (a treatment that boosts your immune system to fight cancer) with a targeted type of radiation called SBRT, which precisely delivers high-dose radiation to multiple cancer spots. The main goal is to see if this combination helps control metastatic cancer (cancer that has spread) better than standard care.
Lexington, KentuckyAges 18–99 - NCT05435248RecruitingPhase 1/Phase 2
Study drug for advanced lung cancer with a specific EGFR change
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
Guangzhou, GuangdongAges 18 years+ - NCT07619339RecruitingPhase 1
Study of tepotinib and ivonescimab for non-small cell lung cancer
This trial tests a combination of two drugs, tepotinib and ivonescimab, for people with a certain type of advanced non-small cell lung cancer that has a change called MET exon 14 skipping. The treatment aims to shrink tumors or slow their growth.
Basking Ridge, New JerseyAges 18 years+ - NCT07014202RecruitingPhase 2
Radiation therapy after chemo-immunotherapy for lung cancer
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06505824RecruitingPhase 1
Study of BL-M14D1 for advanced lung cancer and other solid tumors
This trial tests a new drug, BL-M14D1, for people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have no standard treatment. The goal is to see if the drug is safe and possibly effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06472804Recruiting
Insomnia in advanced lung cancer patients
This study looks at how common insomnia (trouble sleeping) is in people with advanced lung cancer. It aims to better understand sleep problems so doctors can help patients sleep better.
Rochester, MinnesotaAges 18 years+ - NCT05406999RecruitingPhase 2
Intense hormone treatment before prostate surgery for high-risk cancer
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
Nanjing, JiangsuAges 18–80 - NCT06020430Recruiting
Skipping routine radiation for advanced lung cancer after immunotherapy and chemo
This trial tests whether it is safe to skip routine radiation to the tumor bed in patients with stage III lung cancer that has responded well to immunotherapy and chemotherapy. It aims to reduce side effects while still controlling the cancer.
Wuhan, HubeiAges 18–75 - NCT07393555RecruitingPhase 2
Treatment for advanced lung cancer after targeted therapy and chemotherapy
This study tests a new treatment for advanced non-small cell lung cancer that has stopped responding to targeted therapy and chemotherapy. The goal is to find a treatment that works better for people whose cancer has certain genetic changes.
Berkeley, CaliforniaAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Daphne, AlabamaAges 18 years+ - NCT05037331Recruiting
Osimertinib for advanced EGFR-mutated lung cancer
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
SingaporeAges 21–99 - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Daphne, AlabamaAges 18 minutes+ - NCT06644430Recruiting
Burning lung spots plus systemic therapy for liver cancer
This trial tests whether burning away a few cancer spots in the lungs (called ablation) can help people with liver cancer who are already on a systemic treatment. If you have stable liver cancer and only a few lung spots that haven't grown, you may be eligible.
Beijing, Beijing MunicipalityAges 18–80 - NCT06019455Recruiting
How patients participate in lung and esophageal cancer care
This study looks at how much patients with lung or esophageal cancer get involved in decisions about their care when they receive chemotherapy and radiation together. It aims to learn what helps or challenges patients in taking an active role.
GuangzhouAges 18–75 - NCT07563738RecruitingPhase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Irving, TexasAges 18 years+
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced lung cancer?
- Yes. Clin2 currently lists 1,300 recruiting advanced lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- EGFR Mutant Advanced Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.